Regenxbio Inc
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne ; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku ; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis ' ZOLGENSMA ®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people.
Current Price
$5.72
-8.41%GoodMoat Value
$8.23
43.9% undervaluedRegenxbio Inc (RGNX) Social Sentiment
RGNX Social Sentiment Analysis
Social media sentiment analysis for Regenxbio Inc (RGNX). Track bullish and bearish sentiment, mention volume, and BuzzScore trends from StockTwits and Reddit. Social sentiment provides a crowd-sourced view of investor confidence in RGNX.
Current stock price: $5.72. Market cap: $295.23M. This page displays sentiment timelines, bullish vs bearish ratios, total mention counts, peak BuzzScore data, and source breakdowns for RGNX. The sentiment data is updated regularly to reflect the latest social media activity.
Social sentiment is one of many signals to consider when evaluating a stock. High bullish sentiment combined with strong fundamentals may reinforce a buy thesis. Use GoodMoat's sentiment tracking alongside quality analysis, financial data, and valuation models to make well-informed investment decisions about Regenxbio Inc.